Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib Pharmacokinetics in Renal Impairment
NCT03660241Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2018
- Primary completion
- Nov 2019
- Countries
- 2
01
Overview
Phase 1, open-label trial of abrocitinib in atopic dermatitis (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) for PF-04965842, Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-04965842 and 4 more. Started Oct 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03660241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660241.